Breast Cancer Immunotherapy: Latest Advances and Treatments
Learn the latest in immunotherapy for breast cancer. Checkpoint inhibitors now come with years of survival data behind them, and cellular therapies point toward an even more personalized future.
SurvivingBreastCancer.org Editorial EDUCATION | IMMUNOTHERAPY
Key Takeaways
Immunotherapy helps the immune system identify and attack breast cancer cells.
Pembrolizumab continues to improve long-term outcomes for some people with triple-negative breast cancer (TNBC).
New antibody-drug conjugates give oncologists more ways to treat advanced and metastatic disease.
Researchers are studying CAR T-cell therapy and other personalized treatments for breast cancer.
Biomarker testing can reveal whether immunotherapy or targeted therapy may fit your diagnosis.
Your oncology team can explain how the latest breast cancer treatments apply to your individual care plan.
A breast cancer diagnosis brings a flood of new vocabulary, and immunotherapy often tops the list of confusing terms. Put simply, immunotherapy trains your immune system to recognize and attack cancer cells, rather than relying solely on chemotherapy or radiation. For individuals and loved ones navigating treatment decisions in 2026, several genuine breakthroughs deserve attention.
Checkpoint Inhibitors Keep Proving Their Worth
Cancer cells can sometimes avoid detection by using proteins that act as “off switches” on immune cells. Immune checkpoint inhibitors block those signals, allowing the immune system to respond more effectively.
According to the National Cancer Institute, pembrolizumab, sold under the brand name Keytruda, remains the only immunotherapy drug specifically approved to treat breast cancer. Doctors generally use it in combination with other medications rather than on its own.
Seven-year follow-up data from the KEYNOTE-522 trial, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showed encouraging results: pairing pembrolizumab with chemotherapy before surgery, then continuing it afterward, improved both distant disease-free survival and overall survival in high-risk, early-stage TNBC patients. That long-term data matters enormously: it shows oncologists and patients that the benefit holds up not just in the months after treatment, but years later.
Researchers selected TNBC for early immunotherapy trials because this subtype tends to respond better to immune-based approaches than hormone-receptor-positive cancers do. If you or a loved one has been diagnosed with TNBC, ask your oncology team directly whether checkpoint inhibitor therapy fits your treatment plan.
Antibody-Drug Conjugates Pair Up With Immunotherapy
Antibody-drug conjugates, or ADCs, deliver chemotherapy directly to cancer cells while sparing healthy tissue. In 2026, these drugs made real strides in metastatic TNBC. The FDA approved Dato-DXd for metastatic TNBC patients who don’t qualify for immunotherapy. The combination of Dato-DXd and a newer ADC called iza-bren improved both progression-free and overall survival compared with standard chemotherapy. Oncologists increasingly combine ADCs with immunotherapy drugs, giving patients more options when a single approach falls short.
Cellular Therapies Enter the Picture
CAR T-cell therapy has transformed treatment for certain blood cancers, and researchers are now testing it for breast cancer, too. Early-phase trials target antigens such as HER2, ROR1, MUC1, mesothelin, and B7-H3. These trials remain in their infancy, and scientists still face real obstacles, including finding antigens unique enough to breast tumors and overcoming the tumor’s ability to suppress immune attacks. Keep an eye on this research; it represents one of the field’s most promising long-term directions.
A New Kind of Targeted Drug Joins the Toolkit
May 2026 brought approval of vepdegestrant, sold as Veppanu, the first-ever approved PROTAC protein degrader, for patients with ESR1-mutated, hormone-receptor-positive, HER2-negative advanced breast cancer. While not a traditional immunotherapy, this drug works alongside immune-based treatments in many individuals’ broader care plans and signals how quickly the treatment landscape keeps shifting.
What This Means for You
Every advance above shares a common thread: oncologists increasingly combine tools rather than relying on any single treatment. Immunotherapy, ADCs, targeted therapies, and even AI-driven screening now work together to catch cancer earlier and treat it more precisely.
Treatment jargon can be confusing. Bring a list of questions to every oncology appointment, and don’t hesitate to ask your care team to explain terms in plain language. Ask specifically whether biomarker testing, such as PD-L1 status, could open up immunotherapy options for your specific diagnosis.
Breast cancer treatment in 2026 looks meaningfully different than it did even five years ago. Checkpoint inhibitors now come with years of survival data behind them, ADCs give oncologists new ways to target hard-to-treat cancers, and cellular therapies point toward an even more personalized future. Talk with your oncologist about which of these advances might apply to your situation, and remember that research keeps moving forward every single month.
Count On Us
For additional support navigating your diagnosis, treatment decisions, and life after a breast cancer diagnosis, visit SurvivingBreastCancer.org, which offers programs and trusted educational resources on symptoms, testing, treatment options, surgery, and more, plus podcasts featuring professionals, advocates, and caregivers.
Your support helps SurvivingBreastCancer.org continue providing knowledge, connection, and community to those impacted by breast cancer, every day, all year long.
Note: This article is designed to provide general information and is not meant to replace professional medical advice. Always discuss your options with your healthcare provider.
Watch on YouTube: How MBC Treatments Target Cancer Cells
Read More:
On the Podcast: Breast Cancer Conversations
Episode 202. Good News for Triple Negative Breast Cancer: A Vaccine and Hope for the Future
